CD5 is A potential selecting ligand for B-cell surface immunoglobulin: a possible role in maintenance and selective expansion of normal and malignant B cells
- PMID: 10674908
- DOI: 10.3109/10428190009148857
CD5 is A potential selecting ligand for B-cell surface immunoglobulin: a possible role in maintenance and selective expansion of normal and malignant B cells
Abstract
Although the function of CD5 on B cells is unknown, previous studies suggested that CD5 interaction with V(H) framework regions of surface immunoglobulins (Igs) may contribute to survival and expansion of B cells. Here we used B-chronic lymphocytic leukemia (B-CLL) cells and transformed B-cell lines from normal and B-CLL patients to study CD5-Ig interactions. Immobilized Ig binds and permits isolation of CD5 from lysates of CD5-expressing cell lines. Immunoglobulins or Fab fragments of different V(H) families varied in their effectiveness as inhibitors of anti-CD5 staining of CLL cells, appendix and tonsil tissue sections. Human Ig also binds to purified recombinant CD5. We show here for the first time that the unconventional Ig-CD5 interaction maps to the extracellular CD5-D2 domain whereas conventional epitopes recognized by anti-CD5 antibodies are localized in the D1 domain of CD5. We propose that interactions of VH framework regions with CD5 as a ligand may maintain, select or expand normal, autoimmune or transformed B cells and also contribute to skewing of the normal V(H) repertoire.
Similar articles
-
CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences.J Exp Med. 1996 Oct 1;184(4):1279-84. doi: 10.1084/jem.184.4.1279. J Exp Med. 1996. PMID: 8879199 Free PMC article.
-
IgM expressed by leukemic CD5(+) B cells binds mouse immunoglobulin light chain.J Mol Recognit. 2001 Jul-Aug;14(4):245-53. doi: 10.1002/jmr.539. J Mol Recognit. 2001. PMID: 11500971
-
CD5 and immunoglobulin V gene expression in B-cell lymphomas and chronic lymphocytic leukemia.Blood. 1990 Apr 1;75(7):1518-24. Blood. 1990. PMID: 1690580
-
CD5 and other superantigens may select and maintain rabbit self-renewing B-lymphocytes and human B-CLL cells.Curr Top Microbiol Immunol. 2000;252:87-96. doi: 10.1007/978-3-642-57284-5_10. Curr Top Microbiol Immunol. 2000. PMID: 11125495 Review. No abstract available.
-
The pathologic significance of the immunoglobulins expressed by chronic lymphocytic leukemia B-cells in the development of autoimmune hemolytic anemia.Leuk Lymphoma. 1998 Jan;28(3-4):285-93. doi: 10.3109/10428199809092684. Leuk Lymphoma. 1998. PMID: 9517500 Review.
Cited by
-
Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease.Front Immunol. 2022 Sep 21;13:966184. doi: 10.3389/fimmu.2022.966184. eCollection 2022. Front Immunol. 2022. PMID: 36211446 Free PMC article.
-
Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents.Cells. 2020 Dec 3;9(12):2589. doi: 10.3390/cells9122589. Cells. 2020. PMID: 33287301 Free PMC article. Review.
-
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.Arthritis. 2010;2010:130646. doi: 10.1155/2010/130646. Epub 2011 Feb 10. Arthritis. 2010. PMID: 22076177 Free PMC article.
-
A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase.J Biol Chem. 2011 Sep 2;286(35):30324-30336. doi: 10.1074/jbc.M111.230102. Epub 2011 Jul 8. J Biol Chem. 2011. PMID: 21757751 Free PMC article.
-
A ligand for CD5 is CD5.J Immunol. 2010 Nov 15;185(10):6068-74. doi: 10.4049/jimmunol.0903823. Epub 2010 Oct 15. J Immunol. 2010. PMID: 20952682 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources